MRT5400/MRT5401 mRNA Influenza Vaccine Description
MRT5400 and MRT5401 are mRNA monovalent flu vaccine candidates coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.
Flu seasons that are dominated by A/H3N2 strain circulation activity tend to be more severe, especially among those considered at-risk such as older adults and younger children.
The two formulations differ in the lipid nanoparticle (LNP) that contains the mRNA.
MRT5400/MRT5401 mRNA Influenza Vaccine Indication
MRT5400/MRT5401 mRNA Influenza vaccine candidates are being developed using new mRNA technology to protect those considered at-risk such as older adults or young children of severe influenza.
MRT5400/MRT5401 mRNA Influenza Vaccine News
August 3, 2021 - Sanofi announced as a part of its endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio.
June 22, 2021 - Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
MRT5400/MRT5401 mRNA Influenza Vaccine Clinical Trial
The Phase 1 trial will evaluate an mRNA-based investigational vaccine against seasonal influenza.
The US-based Phase 1 clinical trial will assess the safety and immunogenicity (immune response) of the monovalent (single-strain) mRNA-based flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus, in up to 280 participants.
The trial will evaluate several dose levels of both vaccine formulations given to healthy adults 18 – 49 years of age.